42 results
8-K
EX-99.1
PYXS
Pyxis Oncology Inc
14 May 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
7:55am
plan to dose an additional 16 patients with a focus on five tumor types of interest based on an assessment of factors including immunohistochemistry
8-K
EX-99.1
PYXS
Pyxis Oncology Inc
21 Mar 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
7:44am
ongoing enrollment on four tumor types of high interest, identified through the assessment of several factors, including, but not limited to, IHC
8-K
EX-99.2
hwjnwidkrwvugr3
21 Mar 24
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
7:44am
8-K
EX-10.1
7xl5g62jfri9y2ptu
28 Feb 24
Pyxis Oncology Announces $50 Million Private Placement
7:02am
8-K
EX-10.2
3p9 r9ldb2qnpvu1
28 Feb 24
Pyxis Oncology Announces $50 Million Private Placement
7:02am
8-K
58g2qpkb
28 Nov 23
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
7:22am
424B3
ft0g3xqenjl4v93h
30 Jun 23
Prospectus supplement
4:05pm
S-4/A
6n9f7ilh
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
j6uds bk1
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
425
EX-99.1
w6ip0lbq
24 May 23
Business combination disclosure
4:55pm
8-K
EX-99.1
wdw3svpid
24 May 23
Regulation FD Disclosure
4:53pm
425
k65fu1a4zf0jrxc4
24 May 23
Business combination disclosure
7:05am
425
191x9iff
24 May 23
Business combination disclosure
7:03am
8-K
EX-2.1
pnkvmh1hrat
24 May 23
Pyxis Oncology to Acquire Apexigen
6:59am